Press Releases Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
7.15 ^USD	+4.08%		+5.30%	-2.32%

Mar. 26	Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	MT
Mar. 26	Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	GL
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA	Mar. 27	AQ
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA	Mar. 26	GL
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	Mar. 08	BU
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results	Feb. 29	GL
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference	Feb. 27	GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	Feb. 22	GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	Feb. 22	AQ
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	Feb. 14	BU
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	Feb. 05	GL
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	Feb. 05	AQ
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	Jan. 30	AQ
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services	Jan. 29	GL
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma	Jan. 05	GL
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts	Jan. 04	GL
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts	Jan. 04	AQ
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH	Jan. 04	AQ
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™	Jan. 03	GL
Torii Pharmaceutical - Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	Dec. 18	AQ
Verrica Pharmaceuticals Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208	Dec. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Press Releases

Filters